Abstract
Background: Ischaemia-reperfusion injury (IRI), a major complication occurring during organ transplantation, involves an initial ischemia insult, due to loss of blood supply, followed by an inflammation-mediated reperfusion injury. A variety of molecular targets and pathways involved in liver IRI have been identified. Gene silencing through RNA interference (RNAi) by means of small interference RNA (siRNA) targeting mediators of IRI is a promising therapeutic approach.
Objective: This study aims at reviewing the use of siRNAs as therapeutic agents to prevent IRI during liver transplantation.
Method: We review the crucial choice of siRNA targets and the advantages and problems of the use of siRNAs.
Results: We propose possible targets for siRNA therapy during liver IRI. Moreover, we discuss how drug delivery systems, namely liposomes, may improve siRNA therapy by increasing siRNA stability in vivo and avoiding siRNA off-target effects.
Conclusion: siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies.
Keywords: Liver transplant, liposomes, drug delivery, ischaemia-reperfusion injury, RNA interference, small interference RNA.
Current Pharmaceutical Design
Title:Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury
Volume: 24 Issue: 23
Author(s): H. Susana Marinho, Paulo Marcelino, Helena Soares and Maria Luísa Corvo*
Affiliation:
- Instituto de Investigacao do Medicamento (iMed.ULisboa), Faculdade de Farmacia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa,Portugal
Keywords: Liver transplant, liposomes, drug delivery, ischaemia-reperfusion injury, RNA interference, small interference RNA.
Abstract: Background: Ischaemia-reperfusion injury (IRI), a major complication occurring during organ transplantation, involves an initial ischemia insult, due to loss of blood supply, followed by an inflammation-mediated reperfusion injury. A variety of molecular targets and pathways involved in liver IRI have been identified. Gene silencing through RNA interference (RNAi) by means of small interference RNA (siRNA) targeting mediators of IRI is a promising therapeutic approach.
Objective: This study aims at reviewing the use of siRNAs as therapeutic agents to prevent IRI during liver transplantation.
Method: We review the crucial choice of siRNA targets and the advantages and problems of the use of siRNAs.
Results: We propose possible targets for siRNA therapy during liver IRI. Moreover, we discuss how drug delivery systems, namely liposomes, may improve siRNA therapy by increasing siRNA stability in vivo and avoiding siRNA off-target effects.
Conclusion: siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies.
Export Options
About this article
Cite this article as:
Marinho Susana H. , Marcelino Paulo , Soares Helena and Corvo Luísa Maria*, Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury, Current Pharmaceutical Design 2018; 24 (23) . https://dx.doi.org/10.2174/1381612824666180807124356
DOI https://dx.doi.org/10.2174/1381612824666180807124356 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Contribution of Dietary Factors to Peroxisome Proliferator-Activated Receptor-Mediated Inflammatory Signaling in Arthritic Diseases
Current Rheumatology Reviews Pexelizumab, an Anti-C5 Complement Antibody for Primary Coronary Revascularization: A New Insight from Old Versions
Cardiovascular & Hematological Disorders-Drug Targets 23Na Magnetic Resonance Imaging for the Determination of Myocardial Viability: The Status and the Challenges
Current Vascular Pharmacology Plant Troponoids: Chemistry, Biological Activity, and Biosynthesis
Current Medicinal Chemistry Novel Drugs and the Response to Hypoxia: HIF Stabilizers and Prolyl Hydroxylase
Recent Patents on Cardiovascular Drug Discovery Interactions between Phytochemicals from Traditional Chinese Medicines and Human Cytochrome P450 Enzymes
Current Drug Metabolism Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design Functional Role of ADP-Ribosyl-Acceptor Hydrolase 3 in poly(ADPRibose) Polymerase-1 Response to Oxidative Stress
Current Protein & Peptide Science UPLC-DAD Assisted Phytochemical Quantitation Reveals a Sex, Ploidy and Ecogeography Specificity in the Expression Levels of Selected Secondary Metabolites in Medicinal Tinospora cordifolia: Implications for Elites’ Identification Program
Current Topics in Medicinal Chemistry Targeting Mitochondrial Oxidative Stress Through Lipoic Acid Synthase: A Novel Strategy to Manage Diabetic Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Current Topics in Medicinal Chemistry Recent Advances in the Development of Anti-Infective Prophylactic and/or Therapeutic Agents Based on Toll-Like Receptor (TLRs)
Recent Patents on Anti-Infective Drug Discovery Tailoring NO Donors Metallopharmaceuticals: Ruthenium Nitrosyl Ammines and Aliphatic Tetraazamacrocycles
Current Medicinal Chemistry Cell Therapy for the Treatment of Chronic Ischemic Heart Disease
Current Pharmaceutical Design Lipid-Induced Modulation of Protective Signalling Pathways in Cardiovascular Disease: The Role of High Density Lipoproteins
Current Signal Transduction Therapy Influence of a Novel Inhibitor (UM8190) of Prolylcarboxypeptidase (PRCP) on Appetite and Thrombosis
Current Medicinal Chemistry High Throughput Metabolomics in Clinical Studies: Review and New Applications to Remote Ischemic Preconditioning
Current Topics in Medicinal Chemistry Expressions of eNOS3 and Ve-Cadherin in Microvascular Endothelium at 7-Day of Reperfused Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets How Unbiased is Non-Targeted Metabolomics and is Targeted Pathway Screening the Solution?
Current Pharmaceutical Biotechnology